Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

被引:263
作者
Ng, Kok Pin [1 ,2 ,3 ]
Pascoal, Tharick A. [1 ]
Mathotaarachchi, Sulantha [1 ]
Therriault, Joseph [1 ]
Kang, Min Su [1 ]
Shin, Monica [1 ]
Guiot, Marie-Christine [4 ]
Guo, Qi [5 ]
Harada, Ryuichi [6 ]
Comley, Robert A. [5 ]
Massarweh, Gassan [7 ]
Soucy, Jean-Paul [7 ]
Okamura, Nobuyuki [8 ]
Gauthier, Serge [3 ]
Rosa-Neto, Pedro [1 ,3 ,9 ,10 ]
机构
[1] McGill Univ, Translat Neuroimaging Lab, Res Ctr Studies Aging, 6825 LaSalle Blvd, Verdun, PQ H4H 1R3, Canada
[2] Natl Inst Neurosci, Dept Neurol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
[3] McGill Univ, Res Ctr Studies Aging, Alzheimers Dis Res Unit, 6825 LaSalle Blvd, Verdun, PQ H4H 1R3, Canada
[4] McGill Univ, Ctr Hosp, Montreal Neurol Inst Hosp, Dept Pathol, 3801 Univ St, Montreal, PQ H3A 2B4, Canada
[5] AbbVie Inc, 1 North Waukegan Rd, N Chicago, IL USA
[6] Tohoku Univ, Dept Pharmacol, Grad Sch Med, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan
[7] McGill Univ, McConnell Brain Imaging Ctr, 3801 Univ St, Montreal, PQ H3A 2B4, Canada
[8] Tohoku Med & Pharmaceut Univ, Div Pharmacol, Fac Med, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan
[9] Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada
[10] McGill Univ, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada
基金
英国医学研究理事会; 加拿大健康研究院;
关键词
F-18-THK5351 tau tracer; Monoamine oxidase-B; Selegiline; Alzheimer's disease; Positron emission tomography; MAO-B; IN-VIVO; AMYLOID-BETA; L-DEPRENYL; PET; ASTROCYTOSIS; TRACER;
D O I
10.1186/s13195-017-0253-y
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: F-18-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of F-18-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on F-18-THK5351 brain uptake using PET and autoradiography. Methods: Eight participants (five mild cognitive impairment, two Alzheimer's disease, and one progressive supranuclear palsy) had baseline F-18-AZD4694 and F-18-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second F-18-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third F-18-THK5351 scan 9-28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after F-18-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. F-18-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline. Results: At baseline, F-18-THK5351 SUVs were highest in the basal ganglia (0.64 +/- 0.11) and thalamus (0.62 +/- 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced F-18-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9-28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on F-18-THK5351 uptake. Conclusions: These results indicate that the interpretation of F-18-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of F-18-THK5351 scans using reference region methods.
引用
收藏
页数:9
相关论文
共 39 条
[1]  
Ad-Dabbagh Y., 2006, Proceedings of the 12th annual meeting of the organization for human brain mapping, page, P2266
[2]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[3]   STAGING OF ALZHEIMERS-DISEASE-RELATED NEUROFIBRILLARY CHANGES [J].
BRAAK, H ;
BRAAK, E .
NEUROBIOLOGY OF AGING, 1995, 16 (03) :271-278
[4]   Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG [J].
Carter, Stephen F. ;
Scholl, Michael ;
Almkvist, Ove ;
Wall, Anders ;
Engler, Henry ;
Langstrom, Bengt ;
Nordberg, Agneta .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (01) :37-46
[5]   Clinical Validation of 18F-AZD4694, an Amyloid-β-Specific PET Radioligand [J].
Cselenyi, Zsolt ;
Jonhagen, Maria Eriksdotter ;
Forsberg, Anton ;
Halldin, Christer ;
Julin, Per ;
Schou, Magnus ;
Johnstrom, Peter ;
Varnas, Katarina ;
Svensson, Samuel ;
Farde, Lars .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) :415-424
[6]   In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390 [J].
Ekelund, Jesper ;
Slifstein, Mark ;
Narendran, Raj ;
Guillin, Olivier ;
Belani, Hemant ;
Guo, Ning-Ning ;
Hwang, Yuying ;
Hwang, Dah-Ren ;
Abi-Dargham, Anissa ;
Laruelle, Marc .
MOLECULAR IMAGING AND BIOLOGY, 2007, 9 (03) :117-125
[7]   MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? [J].
Foley, P ;
Gerlach, M ;
Youdim, MBH ;
Riederer, P .
PARKINSONISM & RELATED DISORDERS, 2000, 6 (01) :25-47
[8]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[9]   SLOW RECOVERY OF HUMAN BRAIN MAO-B AFTER L-DEPRENYL (SELEGELINE) WITHDRAWAL [J].
FOWLER, JS ;
VOLKOW, ND ;
LOGAN, J ;
WANG, GJ ;
MACGREGOR, RR ;
SCHLYER, D ;
WOLF, AP ;
PAPPAS, N ;
ALEXOFF, D ;
SHEA, C ;
DORFLINGER, E ;
KRUCHOWY, L ;
YOO, K ;
FAZZINI, E ;
PATLAK, C .
SYNAPSE, 1994, 18 (02) :86-93
[10]   Inhibition of monoamine oxidase B in the brains of smokers [J].
Fowler, JS ;
Volkow, ND ;
Wang, GJ ;
Pappas, N ;
Logan, J ;
MacGregor, R ;
Alexoff, D ;
Shea, C ;
Schlyer, D ;
Wolf, AP ;
Warner, D ;
Zezulkova, I ;
Cilento, R .
NATURE, 1996, 379 (6567) :733-736